Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12263225

    Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12263179

    Lyme disease-associated T cell receptor-related methods

    Adaptive Biotechnologies Corporation · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12263173

    PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

    Cardiff Oncology, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12263149

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12263148

    Levodopa dosing regimen

    AMNEAL PHARMACEUTICALS LLC · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12263145

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12263165

    Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

    The Board of Regents of the University of Texas System · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12263156

    Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms

    The Board of Regents for Oklahoma State University · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12264154

    Compounds and methods of use

    Tango Therapeutics, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12263159

    Fused ring compound having urea structure

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12264336

    Platform for generating safe cell therapeutics

    The Regents of the University of California · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12263243

    Templated open flocs of anisotropic particles for enhanced pulmonary delivery

    The Board of Regents of the University of Texas System · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12263202

    Method of treating melanocortin-4 receptor pathway-associated disorders

    RHYTHM PHARMACEUTICALS, INC. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. TW 202513047

    KAT6 inhibitors

    BEIGENE SWITZERLAND GMBH [CH] · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12263180

    Method for treatment of COVID-19-associated conditions

    Rigel Pharmaceuticals, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12264149

    Indazole compounds as kinase inhibitors

    TYRA BIOSCIENCES, INC. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12264159

    Functionalized heterocycles as antiviral agents

    Enanta Pharmaceuticals, Inc. · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    INSTITUT PASTEUR DE MONTEVIDEO · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12263227

    Optimized mRNA encoding CAS9 for use in LNPs

    CRISPR THERAPEUTICS AG · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. EP 4529925

    CORTEXOLON-17-ALPHA-PROPIONAT ZUR BEHANDLUNG VON AKNEIFORMEN ERUPTEN

    CASSIOPEA S P A [IT] · Granted Wed Apr 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Tue Mar 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. WO 2025068985

    DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5

    BEIGENE SWITZERLAND GMBH [CH] · Granted Thu Apr 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. WO 2025070337

    ANTICORPS AGONISTE ANTI-MERTK, ANTICORPS BISPÉCIFIQUE ANTI-MERTK ET LEUR UTILISATION

    ASTELLAS PHARMA INC [JP] · Granted Thu Apr 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. WO 2025068281

    CORTÉXOLONE-17α-PROPIONATE POUR LE TRAITEMENT D'ÉRUPTIONS ACNÉIFORMES

    CASSIOPEA S P A [IT] · Granted Thu Apr 03 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12269897

    Anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12269889

    Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12270080

    NcRNA and uses thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12270814

    Kits and methods for prediction and treatment of preeclampsia

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12270050

    Human T cell derived from T cell-derived induced pluripotent stem cell and methods of making and using

    Regents of the University of Minnesota · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12269872

    Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12269858

    Activin receptor type IIB variants and methods of use thereof

    Keros Therapeutics, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12269856

    Hepcidin analogues and uses thereof

    Protagonist Therapeutics, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12269887

    Anti-canine CD16 polypeptides, anti-canine CD64 polypeptides, compositions including same, and methods of using

    Regents of the University of Minnesota · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12269801

    Modified amino acids

    Sutro Biopharma, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12269155

    Multivalent vaccines for rabies virus and coronaviruses

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12269808

    Amino dithioperacid thioester compound, preparation method therefor, and use thereof

    EAST CHINA NORMAL UNIVERSITY · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12269820

    Piperazine substituted indazole compounds as inhibitors of PARG

    IDEAYA Biosciences, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12268730

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12269831

    Modulators of cystic fibrosis transmembrane conductance regulator

    Vertex Pharmaceuticals Incorporated · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12268753

    Nanomaterials comprising a biodegradable feature

    Beam Therapeutics Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12268749

    Cell-penetrating peptides

    United Kingdom Research and Innovation · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12268693

    Pharmaceutical compositions comprising a tolfenamic acid

    AXSOME THERAPEUTICS, INC. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12268683

    Compounds and methods for synergistic activation of M channels

    The Regents of the University of California · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12268694

    Combination pharmaceutical agents as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12268688

    Compositions and methods of use for modified release minoxidil

    Veradermics Incorporated · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12268831

    Swallowable drug delivery device and methods of drug delivery

    Rani Therapeutics, LLC · Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.